Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models

References

• El-SeragHBRudolphKLHepatocellular carcinoma: epidemiology and molecular carcinogenesisGastroenterology20071322557257617570226
   PubMed Web of Science ®Google Scholar
• LlovetJMBruixJNovel advancements in the management of hepatocellular carcinoma in 2008J Hepatol200848Suppl 1S20S3718304676
   PubMed Web of Science ®Google Scholar
• BruixJShermanMManagement of hepatocellular carcinoma: an updateHepatology2011531020102221374666
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med200835937839018650514
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med20131932933623396206
   PubMed Web of Science ®Google Scholar
• KesariSRandazzoBPValyi-NagyTTherapy of experimental human brain tumors using neuroattenuated herpes simplex virus mutantLab Invest1995736366487474937
   PubMed Web of Science ®Google Scholar
• KucharczukJCRandazzoBChangMYUse of a “replication restricted” herpes virus to treat experimental human malignant mesotheliomaCancer Res1997574664719012475
   PubMed Web of Science ®Google Scholar
• RandazzoBPBhatMGKesariSFraserNWBrownSMTreatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutantJ Invest Dermatol19971089339779182825
   PubMed Web of Science ®Google Scholar
• CoukosGMakrigiannakisAKangEHUse of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancerClin Cancer Res199951523153710389942
   PubMed Web of Science ®Google Scholar
• RamplingRCruikshankGPapanastassiouVToxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Ther2000785986610845724
   PubMed Web of Science ®Google Scholar
• PapanastassiouVRamplingRFraserMThe potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoral injection into human malignant glioma: a proof of principle studyGene Ther2002939840611960316
   PubMed Web of Science ®Google Scholar
• HarrowSPapanastassiouVHarlandJHSV1716 injection into the brain adjacent to tumor following surgical resection of high-grade glioma: safety data and long term survivalGene Ther2004111648165815334111
   PubMed Web of Science ®Google Scholar
• MacKieRMStewartBBrownSMIntralesional injection of herpes simplex virus 1716 in metastatic melanomaLancet200135752552611229673
   PubMed Web of Science ®Google Scholar
• MaceATGanlyISoutarDSBrownSMPotential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinomaHead Neck2008301045105118615711
   PubMed Web of Science ®Google Scholar
• ArgnaniRMarconiPVolpiICharacterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancerLiver Int2011311542155322093330
   PubMed Web of Science ®Google Scholar
• FokaPPourchetAHernandez-AlcocebaRNovel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectorsJ Gene Med20101295696721104973
   PubMed Web of Science ®Google Scholar
• SantamaríaEMoraMICarro-RoldánEIdentification of replication-competent HSV-1 Cgal+ strain targets in a mouse model of human hepatocarcinoma xenograftJ Proteomics20097315316019540947
   PubMed Web of Science ®Google Scholar
• SongTJEisenbergDPAdusumilliPSHezelMFongYOncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell linesJ Gastrointest Surg20061053254216627219
   PubMed Web of Science ®Google Scholar
• MiyatakeSGene therapy using tissue-specific replication competent HSVHum Cell20021513013712703543
   PubMedGoogle Scholar
• XueFDongCYSuYTumor-targeted therapy with a conditionally replicating mutant of HSV-1 induces regression of xenografted human hepatomasCancer Biol Ther200541234123916357508
   PubMed Web of Science ®Google Scholar
• ZagerJSDelmanKAMalhotraSCombination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancerMol Med2001756156811591892
   PubMed Web of Science ®Google Scholar
• PawlikTMNakamuraHYoonSSOncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirusCancer Res2000602790279510850415
   PubMed Web of Science ®Google Scholar
• MiyatakeSITaniSFeigenbaumFHepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivoGene Ther1999656457210476216
   PubMed Web of Science ®Google Scholar
• ConnerJBraidwoodLBrownSMA strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion proteinGene Ther2008151579159218701918
   PubMed Web of Science ®Google Scholar
• ConnerJBraidwoodLExpression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacyCancer Gene Ther20121949950722595793
   PubMed Web of Science ®Google Scholar
• ToyodaHKumadaTKiriyamaSComparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in JapanAm J Gastroenterol20051001764177116086713
   PubMed Web of Science ®Google Scholar
• YeoWMokTSZeeBA randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinomaJ Natl Cancer Inst2005971532153816234567
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol200910253419095497
   PubMed Web of Science ®Google Scholar
• HeoJBreitbachCJMoonASequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMol Ther2011191170117921427706
   PubMed Web of Science ®Google Scholar
• KirnDHThorneSHTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNat Rev Cancer20099647119104515
   PubMed Web of Science ®Google Scholar
• KimJHOhJYParkBHSystemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSFMol Ther20061436137016905462
   PubMed Web of Science ®Google Scholar
• ParatoKABreitbachCJLe BoeufFThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther20122074975822186794
   PubMed Web of Science ®Google Scholar
• KemenyNBrownKCoveyAPhase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liverHum Gene Ther2006171214122417107303
   PubMed Web of Science ®Google Scholar
• FongYKimTBhargavaAA herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancerMol Ther20091738939419018254
   PubMed Web of Science ®Google Scholar
• GeevargheseSKGellerDAde HaanHAPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverHum Gene Ther2010211119112820486770
   PubMed Web of Science ®Google Scholar